Shah Disha D, Chorawala Mehul R, Raghani Neha R, Patel Rajanikant, Fareed Mohammad, Kashid Vivekanand A, Prajapati Bhupendra G
Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Navrangpura, Ahmedabad, Gujarat, 380009, India.
Department of Pharmacology and Pharmacy Practice, Saraswati Institute of Pharmaceutical Sciences, Gandhinagar, Gujarat, 382355, India.
Med Oncol. 2025 Mar 18;42(4):117. doi: 10.1007/s12032-025-02641-4.
Tumor microenvironment (TME) denotes the non-cancerous cells and components presented in the tumor, including molecules produced and released by them. Interactions between cancer cells, immune cells, stromal cells, and the extracellular matrix within the TME create a dynamic ecosystem that can either promote or hinder tumor growth and spread. The TME plays a pivotal role in either promoting or inhibiting tumor growth and dissemination, making it a critical factor to consider in the development of effective cancer therapies. Understanding the intricate interplay within the TME is crucial for devising effective cancer therapies. Combination therapies involving inhibitors of immune checkpoint blockade (ICB), and/or chemotherapy now offer new approaches for cancer therapy. However, it remains uncertain how to best utilize these strategies in the context of the complex tumor microenvironment. Oncogene-driven changes in tumor cell metabolism can impact the TME to limit immune responses and present barriers to cancer therapy. Cellular and acellular components in tumor microenvironment can reprogram tumor initiation, growth, invasion, metastasis, and response to therapies. Components in the TME can reprogram tumor behavior and influence responses to treatments, facilitating immune evasion, nutrient deprivation, and therapeutic resistance. Moreover, the TME can influence angiogenesis, promoting the formation of blood vessels that sustain tumor growth. Notably, the TME facilitates immune evasion, establishes a nutrient-deprived milieu, and induces therapeutic resistance, hindering treatment efficacy. A paradigm shift from a cancer-centric model to a TME-centric one has revolutionized cancer research and treatment. However, effectively targeting specific cells or pathways within the TME remains a challenge, as the complexity of the TME poses hurdles in designing precise and effective therapies. This review highlights challenges in targeting the tumor microenvironment to achieve therapeutic efficacy; explore new approaches and technologies to better decipher the tumor microenvironment; and discuss strategies to intervene in the tumor microenvironment and maximize therapeutic benefits.
肿瘤微环境(TME)是指肿瘤中存在的非癌细胞和成分,包括它们产生和释放的分子。肿瘤微环境中的癌细胞、免疫细胞、基质细胞和细胞外基质之间的相互作用形成了一个动态生态系统,该系统既可以促进也可以阻碍肿瘤的生长和扩散。肿瘤微环境在促进或抑制肿瘤生长和扩散方面起着关键作用,使其成为有效癌症治疗开发中需要考虑的关键因素。了解肿瘤微环境内错综复杂的相互作用对于设计有效的癌症治疗方法至关重要。涉及免疫检查点阻断(ICB)抑制剂和/或化疗的联合疗法现在为癌症治疗提供了新方法。然而,在复杂的肿瘤微环境背景下如何最佳利用这些策略仍不确定。癌基因驱动的肿瘤细胞代谢变化会影响肿瘤微环境,限制免疫反应,并为癌症治疗带来障碍。肿瘤微环境中的细胞和非细胞成分可以重新编程肿瘤的起始、生长、侵袭、转移以及对治疗的反应。肿瘤微环境中的成分可以重新编程肿瘤行为并影响对治疗的反应,促进免疫逃逸、营养剥夺和治疗抗性。此外,肿瘤微环境可以影响血管生成,促进维持肿瘤生长的血管形成。值得注意的是,肿瘤微环境促进免疫逃逸,建立营养匮乏的环境,并诱导治疗抗性,从而阻碍治疗效果。从以癌症为中心的模式向以肿瘤微环境为中心的模式转变彻底改变了癌症研究和治疗。然而,有效靶向肿瘤微环境内的特定细胞或途径仍然是一项挑战,因为肿瘤微环境的复杂性给设计精确有效的疗法带来了障碍。本综述强调了在靶向肿瘤微环境以实现治疗效果方面的挑战;探索更好地解读肿瘤微环境的新方法和技术;并讨论干预肿瘤微环境并最大化治疗益处的策略。
Crit Rev Oncol Hematol. 2024-9
Front Immunol. 2025-4-7
Clin Transl Oncol. 2025-5
Front Oncol. 2025-8-8
Quant Imaging Med Surg. 2024-8-1
Signal Transduct Target Ther. 2024-7-17
Int J Pharm. 2024-7-20
Asian Pac J Cancer Prev. 2024-3-1